Fig. 5

Immunohistochemical analysis of PRTN3 in VSCC. An example of PRTN3 staining performed on the tumour tissue section, image taken at × 20 magnification (A). The percentage of PRTN3 positive neoplastic cells in vulvar precancers (HSIL; n = 6 and dVIN; n = 2), d-fVSCC (n = 42), progVSCC (n = 40) and recurrent VSCC (n = 4) (B). Survival curves (time to progression) according to the proportion of PRTN3 positive cancer cells (C) and macrophages (D) in primary VSCC tumours (n = 64). PFS progression-free survival, ≤ 3% and > 3%, proportions of PRTN3 + cancer cells, ≤ 15% and > 15%, proportions of PRTN3 + macrophages